Prologue: Can We Deliver Macro Peptides Orally?

On Demand

Location:Online Only

Prologue Speaker(s)

Jenna Walker, PhD

Senior Advisor
Eli Lilly

Lately, the oral peptide drugs have been focused to develop due to the successful development of Rybelsus and Mycapssa. However, their large molecular weight and stability issue in the GI tract are two major obstacles. In this session, from molecular selection, and permeability evaluation, to formulation development, what is the criteria, reasoning and how those are developed with PK results as well as either clinical PK outcome or regulatory prospective will be presented. Smooth transition from preclinical to clinical, and regulatory aspects will be focused on and the newest in vitro methods including AI learning to evaluate in vivo bioperformance of macropeptides will be introduced.

To view all Prologues, visit our library here and click "Enroll".

Learning Objectives:

Upon completion, participants will be able to understand the underlying challenges associated with oral peptide devliery including how physiological barriers complicate the formulation and delivery approaches.
Upon completion, participants will understand how in vitro screening tools that are traditionally used for small molecules are not well established for oral peptides
Upon completion, participants will be understand how preclinical studies are critical to assessing the performance of oral peptides, yet they come with many considerations and challenges related to how they translate into humans
Upon completion, participants will be able to understand that we are far from predicting oral peptide performance with in silico modelling and that we must continue to build our mechanistic understanding and library of formulations to help train models.